Monogram Biosciences, Inc. (Nasdaq:MGRM) today announced that three presentations related to the HERmark® Breast Cancer Assay and VeraTag™ technology will be made at the 45^th meeting of the American Society for Clinical Oncology (ASCO) in Orlando.

“Breast cancers are heterogeneous. Tumors express distinct levels of proteins that may impact the therapeutic effectiveness of particular drugs. Even when tumors are defined as ‘HER2-positive’, clinical responses to HER2-target therapies are varied, but it hasn’t been clear what accounts for the observed differences in outcome,” said Michael Bates, M.D. Monogram Vice President of Clinical Research. “Using the VeraTag technology, we now have clinical data suggesting that precise quantification of HER2 and HER3 expression levels in FFPE specimens allows us to identify multiple sub-populations of patients with HER2-positive metastatic breast cancer that experience different clinical outcomes following treatment with trastuzumab. Taken together, these studies demonstrate the promise of the VeraTag technology to aid in the development of personalized treatment strategies for patients with breast cancer.”

Following are the details for each embargoed session:

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, including statements regarding the demand and outlook for our products, including our HERmark assays, our plans for further developing our oncology franchise, including the conduct and outcome of planned clinical studies and the possible launch of an assay to measure resistance to Her2 targeted drugs such as Herceptin®. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: risks and uncertainties relating to the performance and acceptance of our products; the growth in revenues from all products, including HERmark; the risk that our VeraTag assays, including HERmark, may not predict response to particular therapeutic agents; the risk that we may not be able to obtain additional cohorts of patient samples for additional VeraTag studies, our ability to successfully conduct clinical studies on our expected timelines and the results obtained from those studies; whether larger confirmatory clinical studies will confirm the results of initial studies; whether we will be able to develop, validate and launch assays which measure resistance to Her2 targeted drugs; expected reliance on a few customers for the majority of our revenues; the renewal of certain customer agreements; the impact of our expense reduction programs; our ability to retain and hire key employees; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including HERmark; whether the draft guidance on Multivariate Index Assays issued by the FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, G.E. and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future to repay our convertible debt in the event it is not converted to equity and/or to maintain operations, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

HERmark is a registered trademark and VeraTag is a trademark of Monogram Biosciences, Inc. Herceptin is a registered trademark of Genentech, Inc.

Monogram Biosciences, Inc.
Alfred G. Merriweather, 650-624-4576 (Chief Financial Officer)
amerriweather@monogrambio.com
or
Feinstein Kean Healthcare
Jeremiah Hall, 415-677-2700
jeremiah.hall@fkhealth.com